logo-loader

IQ-AI's David Smith updates on patents and StoneChecker FDA process

Published: 08:33 01 Nov 2018 GMT

David Smith, chief executive of IQ-AI Limited's (LON:IQAI)  operating subsidiaries, spoke to Proactive London's Andrew Scott about the recent filing of a patent for gadolinium-free magnetic resonance imaging (MRI) scan.

Over the past decade, research has shown the potential toxicity of gadolinium-based products and how they are retained in the body for several years.

Smith also talks through how the FDA approval process is coming along for their kidney stone medical imaging software StoneChecker.

Once approved, the group aims to launch the software in the US, India and China by the end of the year while commercial sales in the UK are expected to begin in the fourth quarter.

IQ-AI advances glioblastoma clinical trial, eyes phase two in 2025

Dr Jennifer Connelly, MD, the Principal Investigator (PI) of the IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) sponsored phase one clinical trial that is being conducted at the Medical College of Wisconsin, joined Proactive's Stephen Gunnion with a positive update from its treatment for recurring...

on 23/2/24